Form 4: Artivion Director Anthony Semedo Receives Restricted Stock Grant

Artivion, Inc. Director Anthony B. Semedo was granted 6,325 shares of common stock as a Restricted Stock Award, vesting in May 2026.

Summary

• Anthony B. Semedo, a Director of Artivion, Inc. (AORT), acquired 6,325 shares of common stock on May 22, 2025.
• The acquisition was an RSA (Restricted Stock Award) grant with a price of $0 per share.
• These granted shares are scheduled to vest on May 22, 2026, in accordance with the company's Equity and Cash Incentive Plan.
• Following this transaction, Mr. Semedo directly beneficially owns 41,984 shares of Artivion common stock.
• Additionally, Mr. Semedo indirectly owns 600 shares through his spouse.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as it indicates a standard compensation practice that aligns director interests with the company's long-term performance, without any negative implications.

Positives

• The grant of Restricted Stock Awards to a director aligns management's interests with long-term shareholder value.
• The vesting schedule provides an incentive for the director to remain with the company and contribute to its performance over the next year.

Future Outlook

The document indicates a future vesting event for the granted shares on May 22, 2026, which is tied to the company's Equity and Cash Incentive Plan.

Industry Context

This Form 4 filing reflects a standard practice of executive and director compensation within publicly traded companies, where equity grants like Restricted Stock Awards are used to incentivize long-term performance and align interests with shareholders. Such grants are common across various industries, including the medical technology sector where Artivion operates.

Comparison to Industry Standards

• The use of Restricted Stock Awards (RSAs) as a component of director compensation is a common practice across publicly traded companies, including those in the medical device and biotechnology sectors, such as Medtronic, Edwards Lifesciences, or Boston Scientific, which often utilize similar equity incentive plans to attract and retain talent and align interests with shareholders.
• The vesting period of one year for this RSA grant is within typical industry ranges, which can vary from immediate vesting to multi-year schedules, depending on the company's compensation philosophy and the specific role.

Stakeholder Impact

• Shareholders: The grant of equity to a director can be seen as a positive step towards aligning management's interests with shareholder value, potentially leading to better long-term performance.
• Employees: While not directly impacting all employees, such compensation practices for leadership can set a precedent for incentive structures within the company.

Next Steps

• The 6,325 RSA shares granted to Anthony B. Semedo are scheduled to vest on May 22, 2026.

Key Dates

Recommendation

Keywords

Artivion, AORT, SEC Form 4, Restricted Stock Award, RSA, Insider Transaction, Director Compensation, Equity Grant, Stock Ownership, Corporate Governance